aVaxziPen Announces Positive Data in Multiple Diseases on Novel Needle-Free Vaccine, Thermally Stable Delivery Platform at World Vaccine Congress

3rd April 2023

In vivo data demonstrates immune equivalence to traditional needle and syringe injection when using a needle-free solid dose formulation Oxford, UK, 3 April 2023 – aVaxziPen, a biotech company developing a novel needle-free vaccine delivery platform, announces the presentation of data at the World Vaccine Congress (WVC) in Washington, USA. The company will present a… read more